Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-08-2016 | Retinal Disorders

Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy

Authors: Seoung Hyun An, Yoon Hyung Kwon

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 8/2016

Abstract

Purpose

To investigate the effects of topical pranoprofen 0.1 % on acute central serous chorioretinopathy (CSC).

Methods

The medical records of 52 cases (52 patients) of CSC were retrospectively reviewed. Twenty-six patients were treated with topical pranoprofen 0.1 % (treatment group) and 26 patients did not receive treatment (control group). Baseline and follow-up values for visual acuity, subfoveal choroidal thickness (SCT), subretinal fluid (SRF) maximum height, and central macular thickness (CMT) were examined and compared between groups.

Results

In the treatment group, mean SCT decreased from 365.5 ± 52.9 μm at baseline to 288.9 ± 36.1 μm at 6 months after initiation of treatment (p = 0.005). Both SRF maximum height and CMT were also decreased from baseline at 1 month (SRF maximum height, baseline: 221.5 ± 108.4, 1 month: 97.7 ± 54.3 μm, p = 0.002; CMT, baseline: 403.9 ± 114.6, 1 month: 270.1 ± 37.9 μm, p = 0.003). In the control group, SCT decreased throughout the follow-up period, but the change was not significant. Subretinal fluid maximum height and CMT were significantly decreased after 3 months in the control group (SRF, baseline: 265.4 ± 112.4 μm, 6 months: 64.8 ± 116.9 μm, p = 0.005; CMT, baseline: 459.1 ± 104.9 μm, 6 months: 304.6 ± 92.8 μm, p < 0.001). Visual acuity was improved from baseline in both groups after 6 months, but the improvement was only significant in the treatment group (p = 0.002). The rate of disease recurrence was lower in the treatment group (23 %) than in the control group (38 %), but this difference between groups was not statistically significant (p = 0.229, chi-square test).

Conclusions

Topical pranoprofen 0.1 % was effective in treating acute CSC, as demonstrated by an increase in visual acuity and a decrease in SRF, SCT, and CMT after treatment. These results suggest that topical pranoprofen 0.1 % may be useful in treating patients with acute CSC.

Piccolino FC, Borgia L (1994) Central serous chorioretinopathy and indocyanine green angiography. Retina 14:231–242CrossRefPubMed

Lacono P, Battaglia PM, Papayannis A, La Spina C, Varano M, Bandello F (2015) Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT. Graefes Arch Clin Exp Ophthalmol. doi:10.1007/s00417-014-2899-5

Gilbert CM, Owens SL, Smith PD, Fine SL (1984) Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 68:815–820CrossRefPubMedPubMedCentral

Baran NV, Gürlü VP, Esgin H (2005) Long-term macular function in eyes with central serous chorioretinopathy. Clin Exp Ophthalmol 33:369–372CrossRef

Loo RH, Scott IU, Flynn HW Jr, Gass JD, Murray TG, Lewis ML, Rosenfeld PJ, Smiddy WE (2002) Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 22:19–24CrossRefPubMed

Caccavale A, Romanazzi F, Imparato M, Negri A, Morano A, Ferentini F (2011) Central serous chorioretinopathy: a pathogenetic model. Clin Ophthalmol 5:239–243. doi:10.2147/OPTH.S171820 CrossRefPubMedPubMedCentral

Wang MS, Sander B, Larsen M (2002) Retinal atrophy in idiopathic central serous chorioretinopathy. Am J Ophthalmol 133:787–793CrossRefPubMed

Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S (2004) Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 111:244–249CrossRefPubMed

Imamura Y, Fujiwara T, Margolis R, Spaide RF (2009) Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 29:1469–1473. doi:10.1097/IAE.0b013e3181be0a83 CrossRefPubMed

10.

Jirarattanasopa P, Ooto S, Tsujikawa A, Yamashiro K, Hangai M, Hirata M, Matsumoto A, Yoshimura N (2012) Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy. Ophthalmology 119:1666–1678. doi:10.1016/j.ophtha.2012.02.021 CrossRefPubMed

11.

Ooto S, Tsujikawa A, Mori S, Tamura H, Yamashiro K, Otani A, Yoshimura N (2011) Retinal microstructural abnormalities in central serous chorioretinopathy and polypoidal choroidal vasculopathy. Retina 31:527–534. doi:10.1097/IAE.0b013e3181eef2db CrossRefPubMed

12.

Kim SW, Oh J, Kwon SS, Yoo J, Huh K (2011) Comparison of choroidal thickness among patients with healthy eyes, early age-related maculopathy, neovascular age-related macular degeneration, central serous chorioretinopathy, and polypoidal choroidal vasculopathy. Retina 31:1904–1911. doi:10.1097/IAE.0b013e31821801c5 CrossRefPubMed

13.

Spaide RF, Goldbaum M, Wong DW, Tang KC, Iida T (2003) Serous detachment of the retina. Retina 23:820–846CrossRefPubMed

14.

Park SY, Kim SM, Song YM, Sung J, Ham DI (2013) Retinal thickness and volume measured with enhanced depth imaging optical coherence tomography. Am J Ophthalmol 156(557–566), e2PubMed

15.

Yang L, Jonas JB, Wei W (2013) Choroidal vessel diameter in central serous chorioretinopathy. Acta Ophthalmol 91:e358–362CrossRefPubMed

16.

Liegl R, Ulbig MW (2014) Central serous chorioretinopathy. Ophthalmologica 232:65–76. doi:10.1159/00036001419 CrossRefPubMed

17.

Zhao L, Qu YX, Li MM, Wang YL (2012) Quantitative evaluation by optical coherence tomography of prophylactic efficiency of Pranopulin on macular edema after cataract surgery. Chin Med J (Engl) 125:4523–4525

18.

Russo A, Costagliola C, Delcassi L, Parmeggiani F, Romano MR, Dell'Omo R, Semeraro F (2013) Topical nonsteroidal anti-inflammatory drugs for macular edema. Mediators Inflamm 2013:476525. doi:10.1155/2013/476525 CrossRefPubMedPubMedCentral

19.

Kim SJ, Flach AJ, Jampol LM (2010) Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 55:108–133. doi:10.1016/j.survophthal.2009.07.005 CrossRefPubMed

20.

Chun BY, Kang SY, Song JS, Kim HM (2010) Comparison of the effects of prophylactic nonsteroidal anti-inflammatory drugs on macular edema after cataract surgery. J Korean Ophthalmol Soc 51:935–940CrossRef

21.

Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F (2013) Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 33:2096–2102. doi:10.1097/IAE.0b013e318297a07a CrossRefPubMed

22.

Singh RP, Sears JE, Bedi R, Schachat AP, Ehlers JP, Kaiser PK (2015) Oral eplerenone for the management of chronic central serous chorioretinopathy. Int J Ophthalmol 8:310–314. doi:10.3980/j.issn.2222-3959.2015.02.17 PubMedPubMedCentral

23.

Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58:103–126. doi:10.1016/j.survophthal.2012.07.004 CrossRefPubMedPubMedCentral

24.

Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. doi:10.1016/j.preteyeres.2015.05.003 PubMed

25.

Alkin Z, Osmanbasoglu OA, Ozkaya A, Karatas G, Yazici AT (2013) Topical nepafenac in treatment of acute central serous chorioretinopathy. Med Hypothesis Discov Innov Ophthalmol 2:96–101PubMedPubMedCentral

26.

Chan WM, Lai TY, Lai RY, Liu DT, Lam DS (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 115:1756–1765CrossRefPubMed

27.

Tittl MK, Spaide RF, Wong D, Pilotto E, Yannuzzi LA, Fisher YL, Freund B, Guyer DR, Slakter JS, Sorenson JA (1999) Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 128:63–68CrossRefPubMed

28.

Brandl C, Helbig H, Gamulescu MA (2014) Choroidal thickness measurements during central serous chorioretinopathy treatment. Int Ophthalmol 34:7–13. doi:10.1007/s10792-013-9774-y CrossRefPubMed

29.

Ratanasukon M, Bhurayanontachai P, Jirarattanasopa P (2012) High-dose antioxidants for central serous chorioretinopathy; the randomized placebo-controlled study. BMC Ophthalmol 16:12–20. doi:10.1186/1471-2415-12-20

30.

Akyol-Salman I, Leçe-Sertöz D, Baykal O (2007) Topical pranoprofen 0.1% is as effective anti-inflammatory and analgesic agent as diclofenac sodium 0.1% after strabismus surgery. J Ocul Pharmacol Ther 23:280–283CrossRefPubMed

31.

Hayasaka Y, Hayasaka S, Zhang XY, Nagaki Y (2003) Effects of topical corticosteroids and nonsteroidal anti-inflammatory drugs on prostaglandin e2-induced aqueous flare elevation in pigmented rabbits. Ophthalmic Res 35:341–344CrossRefPubMed

32.

Tsurumi K, Kyuki K, Yanagihara M, Hasegawa J, Fujimura H (1986) Pharmacological investigations of the new antiinflammatory agent 2-(10,11-dihydro-10-oxodibenzo[b, f]thiepin-2-yl)propionic acid. 5th communication: antiplatelet effect of the drug and antiinflammatory effect of its main metabolite. Arzneimittelforschung 36:1818–1822PubMed

33.

Yamada R, Yamada S, Ishii A, Tane S (1993) Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-1 in blood obtained from patients of idiopathic central serous chorioretinopathy. Nippon Ganka Gakkai Zasshi 97:955–960PubMed

34.

Liu X, Wang S, Kao AA, Long Q (2012) The effect of topical pranoprofen 0.1% on the clinical evaluation and conjunctival HLA-DR expression in dry eyes. Cornea 31:1235–1239. doi:10.1097/ICO.0b013e31824988e5 CrossRefPubMed

35.

Hosoi T, Sasaki M, Baba S, Ozawa K (2009) Effect of pranoprofen on endoplasmic reticulum stress in the primary cultured glial cells. Neurochem Int 54:1–6CrossRefPubMed

36.

Schalnus R (2003) Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 217:89–98CrossRefPubMed

37.

Liew G, Quin G, Gillies M, Fraser-Bell S (2013) Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol 41:201–214. doi:10.1111/j.1442-9071.2012.02848.x CrossRef

38.

Chin EK, Almeida DR, Roybal CN, Niles PI, Gehrs KM, Sohn EH, Boldt HC, Russell SR, Folk JC (2015) Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy. Clin Ophthalmol 11:1449–1156. doi:10.2147/OPTH.S86778 CrossRef

Title: Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy
Authors: Seoung Hyun An
Yoon Hyung Kwon
Publication date: 01-08-2016
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 8/2016
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-015-3215-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2016

Fundus autofluorescence findings in central serous chorioretinopathy using two different confocal scanning laser ophthalmoscopes: correlation with functional and structural status

Interpretation of fundus autofluorescence changes in choriocapillaritis: a multi-modality imaging study

The effectiveness of vitrectomy for diffuse diabetic macular edema may depend on its preoperative optical coherence tomography pattern

Quantitative comparison of disc rim color in optic nerve atrophy of compressive optic neuropathy and glaucomatous optic neuropathy

Modified canaloplasty with suprachoroidal drainage versus conventional canaloplasty—1-year results

Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy